• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SRPK1 通过可能涉及 PI3K/Akt 的机制促进肝癌的恶性转化。

SRPK1 contributes to malignancy of hepatocellular carcinoma through a possible mechanism involving PI3K/Akt.

机构信息

Key Laboratory of Systems Biomedicine (Ministry of Education) of Rui-Jin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

出版信息

Mol Cell Biochem. 2013 Jul;379(1-2):191-9. doi: 10.1007/s11010-013-1641-7. Epub 2013 May 6.

DOI:10.1007/s11010-013-1641-7
PMID:23644876
Abstract

Protein kinases are important regulators in biologic processes. Aberrant expression of protein kinases often causes diseases including cancer. In the present study, we found that the serine-arginine protein kinase 1 (SRPK1) might be involved in hepatocellular carcinoma (HCC) proliferation from a kinome screen using a loss-of-function approach. In clinical samples, SRPK1 was frequently up-regulated in HCCs as compared with adjacent non-tumor tissues at both mRNA and protein levels. Functional studies indicated that overexpression of wild-type SRPK1 promoted HCC cell proliferation, while forced expression of the kinase-dead mutant of SRPK1 or RNA interference against SRPK1 suppressed cell growth and malignancy as measured in soft agar assay. The kinase-dead mutant of SRPK1 also inhibited subcutaneous xenografts' growth of HCC cells in nude mice. Furthermore, western bolt analysis showed overexpression of wild-type SRPK1 enhanced Akt phosphorylation and knockdown of SRPK1 by RNA interference attenuated Akt phosphorylation induced by epidermal growth factor. Meanwhile, overexpression of wild-type SRPK1 also induced a concurrent increase in the total tyrosine phosphorylation of phosphotidylinositol-3 kinase p110α subunit, indicating a functional link between SRPK1 and PI3K/Akt signaling. Our findings suggest that SRPK1 plays an oncogenic role and could be a potential therapeutic target in HCC.

摘要

蛋白激酶是生物过程中的重要调节因子。蛋白激酶的异常表达常导致包括癌症在内的多种疾病。本研究通过功能丧失筛选方法,在激酶组中发现丝氨酸-精氨酸蛋白激酶 1(SRPK1)可能参与肝癌(HCC)的增殖。在临床样本中,与相邻非肿瘤组织相比,SRPK1 在 HCC 中无论是在 mRNA 水平还是蛋白水平均呈高频上调。功能研究表明,野生型 SRPK1 的过表达促进 HCC 细胞增殖,而 SRPK1 的激酶失活突变的强制表达或针对 SRPK1 的 RNA 干扰则抑制了软琼脂测定中细胞生长和恶性程度。SRPK1 的激酶失活突变也抑制了裸鼠中 HCC 细胞皮下异种移植物的生长。此外,western bolt 分析表明,野生型 SRPK1 的过表达增强了 Akt 磷酸化,而 RNA 干扰对 SRPK1 的敲低减弱了表皮生长因子诱导的 Akt 磷酸化。同时,野生型 SRPK1 的过表达也导致磷酯酰肌醇-3 激酶 p110α 亚基的总酪氨酸磷酸化的同时增加,表明 SRPK1 与 PI3K/Akt 信号之间存在功能联系。我们的研究结果表明,SRPK1 发挥致癌作用,可能是 HCC 的潜在治疗靶点。

相似文献

1
SRPK1 contributes to malignancy of hepatocellular carcinoma through a possible mechanism involving PI3K/Akt.SRPK1 通过可能涉及 PI3K/Akt 的机制促进肝癌的恶性转化。
Mol Cell Biochem. 2013 Jul;379(1-2):191-9. doi: 10.1007/s11010-013-1641-7. Epub 2013 May 6.
2
The crucial role of SRPK1 in TGF-β-induced proliferation and apoptosis in the esophageal squamous cell carcinomas.SRPK1在转化生长因子-β诱导的食管鳞状细胞癌增殖和凋亡中的关键作用。
Med Oncol. 2015 Jul;32(7):209. doi: 10.1007/s12032-015-0654-3. Epub 2015 Jun 23.
3
MicroRNA-1296 inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting SRPK1-mediated PI3K/AKT pathway.微小 RNA-1296 通过靶向 SRPK1 介导的 PI3K/AKT 通路抑制肝癌的转移和上皮-间充质转化。
Mol Cancer. 2017 Jun 12;16(1):103. doi: 10.1186/s12943-017-0675-y.
4
Heat shock protein 22 (HSPB8) reduces the migration of hepatocellular carcinoma cells through the suppression of the phosphoinositide 3-kinase (PI3K)/AKT pathway.热休克蛋白 22(HSPB8)通过抑制磷酸肌醇 3-激酶(PI3K)/AKT 通路减少肝癌细胞的迁移。
Biochim Biophys Acta Mol Basis Dis. 2017 Jun;1863(6):1629-1639. doi: 10.1016/j.bbadis.2017.04.021. Epub 2017 Apr 26.
5
FAM9C plays an anti-apoptotic role through activation of the PI3K/Akt pathway in human hepatocellular carcinoma.FAM9C 通过激活人肝癌细胞中的 PI3K/Akt 通路发挥抗凋亡作用。
Oncol Rep. 2013 Sep;30(3):1275-84. doi: 10.3892/or.2013.2592. Epub 2013 Jul 5.
6
Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors.硫酸酯酶 2 可保护肝癌细胞免受 PI3K 抑制剂 LY294002 和 ERK 和 JNK 激酶抑制剂诱导的细胞凋亡。
Liver Int. 2010 Nov;30(10):1522-8. doi: 10.1111/j.1478-3231.2010.02336.x. Epub 2010 Sep 8.
7
APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target.APLN 通过激活 PI3K/Akt 通路促进肝癌发生,是一个有潜力的药物靶点。
Theranostics. 2019 Jul 9;9(18):5246-5260. doi: 10.7150/thno.34713. eCollection 2019.
8
Knockdown of Serine-Arginine Protein Kinase 1 Inhibits the Growth and Migration in Renal Cell Carcinoma Cells.丝氨酸-精氨酸蛋白激酶1的敲低抑制肾癌细胞的生长和迁移。
Oncol Res. 2017 Mar 13;25(3):389-395. doi: 10.3727/096504016X14743324568129. Epub 2016 Sep 22.
9
ERCC6L promotes the progression of hepatocellular carcinoma through activating PI3K/AKT and NF-κB signaling pathway.ERCC6L 通过激活 PI3K/AKT 和 NF-κB 信号通路促进肝癌的进展。
BMC Cancer. 2020 Sep 5;20(1):853. doi: 10.1186/s12885-020-07367-2.
10
Epithelial V-like antigen 1 promotes hepatocellular carcinoma growth and metastasis via the ERBB-PI3K-AKT pathway.上皮细胞 V 样抗原 1 通过 ERBB-PI3K-AKT 通路促进肝癌生长和转移。
Cancer Sci. 2020 May;111(5):1500-1513. doi: 10.1111/cas.14331. Epub 2020 Mar 10.

引用本文的文献

1
Alternative splicing in prostate cancer progression and therapeutic resistance.前列腺癌进展和治疗抵抗中的可变剪接。
Oncogene. 2024 May;43(22):1655-1668. doi: 10.1038/s41388-024-03036-x. Epub 2024 Apr 24.
2
SRPKs: a promising therapeutic target in cancer.SRPKs:癌症中一个有前景的治疗靶点。
Clin Exp Med. 2023 Nov;23(7):3093-3112. doi: 10.1007/s10238-023-01054-9. Epub 2023 Apr 7.
3
Serine-arginine protein kinase 1 (SRPK1) promotes EGFR-TKI resistance by enhancing GSK3β Ser9 autophosphorylation independent of its kinase activity in non-small-cell lung cancer.

本文引用的文献

1
The Akt-SRPK-SR axis constitutes a major pathway in transducing EGF signaling to regulate alternative splicing in the nucleus.Akt-SRPK-SR 轴构成了将 EGF 信号转导到核内调节选择性剪接的主要途径。
Mol Cell. 2012 Aug 10;47(3):422-33. doi: 10.1016/j.molcel.2012.05.014. Epub 2012 Jun 21.
2
Melanoma genome sequencing reveals frequent PREX2 mutations.黑色素瘤基因组测序显示 PREX2 突变频繁。
Nature. 2012 May 9;485(7399):502-6. doi: 10.1038/nature11071.
3
TMEM16A induces MAPK and contributes directly to tumorigenesis and cancer progression.
丝氨酸-精氨酸蛋白激酶 1(SRPK1)通过增强 GSK3β Ser9 自身磷酸化,在非小细胞肺癌中独立于其激酶活性促进 EGFR-TKI 耐药。
Oncogene. 2023 Apr;42(15):1233-1246. doi: 10.1038/s41388-023-02645-2. Epub 2023 Mar 3.
4
Spliceosomal profiling identifies EIF4A3 as a novel oncogene in hepatocellular carcinoma acting through the modulation of FGFR4 splicing.剪接体分析鉴定 EIF4A3 为肝癌中的一种新型癌基因,通过调节 FGFR4 剪接起作用。
Clin Transl Med. 2022 Nov;12(11):e1102. doi: 10.1002/ctm2.1102.
5
MiR-659-3p inhibits osteosarcoma progression and metastasis by inhibiting cell proliferation and invasion via targeting SRPK1.miR-659-3p 通过靶向 SRPK1 抑制骨肉瘤的增殖和侵袭从而抑制其进展和转移。
BMC Cancer. 2022 Aug 29;22(1):934. doi: 10.1186/s12885-022-10029-0.
6
Increased expression of SRPK1 (serine/arginine-rich protein-specific kinase 1) is associated with progression and unfavorable prognosis in cervical squamous cell carcinoma.SRPK1(丝氨酸/精氨酸丰富蛋白特异性激酶 1)的表达增加与宫颈鳞状细胞癌的进展和不良预后相关。
Bioengineered. 2022 Mar;13(3):6100-6112. doi: 10.1080/21655979.2022.2034705.
7
High Serine-arginine Protein Kinase 1 Expression with PTEN Loss Defines Aggressive Phenotype of Prostate Cancer Associated with Lethal Outcome and Decreased Overall Survival.高丝氨酸-精氨酸蛋白激酶1表达伴PTEN缺失定义了与致命结局和总生存期降低相关的前列腺癌侵袭性表型。
Eur Urol Open Sci. 2020 Dec 2;23:1-8. doi: 10.1016/j.euros.2020.11.005. eCollection 2021 Jan.
8
Identification of a novel and potent small molecule inhibitor of SRPK1: mechanism of dual inhibition of SRPK1 for the inhibition of cancer progression.鉴定新型强效的 SRPK1 小分子抑制剂:双重抑制 SRPK1 抑制癌症进展的机制。
Aging (Albany NY). 2020 Dec 3;13(1):163-180. doi: 10.18632/aging.202301.
9
MicroRNAs Involved in Metastasis of Hepatocellular Carcinoma: Target Candidates, Functionality and Efficacy in Animal Models and Prognostic Relevance.微小 RNA 参与肝细胞癌转移:靶候选物、功能和在动物模型中的疗效以及预后相关性。
Cancer Genomics Proteomics. 2020 Jan-Feb;17(1):1-21. doi: 10.21873/cgp.20163.
10
Serine-Arginine Protein Kinase 1 (SRPK1) as a Prognostic Factor and Potential Therapeutic Target in Cancer: Current Evidence and Future Perspectives.丝氨酸/精氨酸蛋白激酶 1(SRPK1)作为癌症的预后因素和潜在治疗靶点:当前证据和未来展望。
Cells. 2019 Dec 19;9(1):19. doi: 10.3390/cells9010019.
TMEM16A 诱导 MAPK 并直接促进肿瘤发生和癌症进展。
Cancer Res. 2012 Jul 1;72(13):3270-81. doi: 10.1158/0008-5472.CAN-12-0475-T. Epub 2012 May 7.
4
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.组蛋白 H3.3 和染色质重塑基因中的驱动突变与儿童弥漫性脑桥胶质瘤。
Nature. 2012 Jan 29;482(7384):226-31. doi: 10.1038/nature10833.
5
WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing.WT1 突变通过改变 VEGF 剪接使 SRPK1 成为下游血管生成靶点。
Cancer Cell. 2011 Dec 13;20(6):768-80. doi: 10.1016/j.ccr.2011.10.016.
6
Type III TGF-β receptor enhances colon cancer cell migration and anchorage-independent growth.III 型转化生长因子-β受体增强结肠癌细胞的迁移和非锚定依赖性生长。
Neoplasia. 2011 Aug;13(8):758-70. doi: 10.1593/neo.11528.
7
Phosphorylation mechanism and structure of serine-arginine protein kinases.丝氨酸-精氨酸蛋白激酶的磷酸化机制与结构。
FEBS J. 2011 Feb;278(4):587-97. doi: 10.1111/j.1742-4658.2010.07992.x. Epub 2011 Jan 12.
8
E2F8 contributes to human hepatocellular carcinoma via regulating cell proliferation.E2F8 通过调节细胞增殖促进人肝癌的发生。
Cancer Res. 2010 Jan 15;70(2):782-91. doi: 10.1158/0008-5472.CAN-09-3082. Epub 2010 Jan 12.
9
Genetic and epigenetic silencing of SCARA5 may contribute to human hepatocellular carcinoma by activating FAK signaling.SCARA5 的遗传和表观遗传沉默可能通过激活 FAK 信号通路促进人肝癌的发生。
J Clin Invest. 2010 Jan;120(1):223-41. doi: 10.1172/JCI38012. Epub 2009 Dec 14.
10
WNK4 enhances the degradation of NCC through a sortilin-mediated lysosomal pathway.WNK4 通过一种网格蛋白介导线粒体途径增强 NCC 的降解。
J Am Soc Nephrol. 2010 Jan;21(1):82-92. doi: 10.1681/ASN.2008121275. Epub 2009 Oct 29.